{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.727","upperLimit":"8.312","value":"3.68"},{"groupId":"OG001","lowerLimit":"0.953","upperLimit":"2.924","value":"1.35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from start of treatment to date of death due to any cause. The percentage (%) event-free probability estimates were obtained from the Kaplan-Meier survival estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with acute myeloid leukemia (AML) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG000","title":"AML Subjects"},{"description":"Subjects with mixed lineage leukemia gene- rearranged acute lymphoblastic leukemia (MLLr-ALL) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG001","title":"MLLr-ALL Subjects"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in FAS population.","reportingStatus":"POSTED","timeFrame":"Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)","title":"Overall Survival With Midostaurin","type":"SECONDARY","unitOfMeasure":"Months"}